Lunai Bioworks Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lunai Bioworks Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Mar 31, 2012 | $0 | Jul 17, 2012 |
| FY2011 | Mar 31, 2011 | $0 | Jul 17, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2016 | $37.5K | Nov 20, 2017 |
| FY2016 | Jun 30, 2015 | ($65.9K) | Sep 28, 2016 |
| FY2016 | Dec 31, 2014 | ($295.7K) | Sep 28, 2016 |
| FY2014 | Dec 31, 2013 | ($76.5K) | Mar 31, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($178.01M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($88.43M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($39.68M) | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | ($113.43M) | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | ($26.72M) | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | ($11.42M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($18.02M) | Sep 23, 2020 |
| FY2018 | Jun 30, 2018 | $471 | Oct 1, 2018 |
| FY2018 | Jun 30, 2017 | ($2.14M) | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | ($1.74M) | Nov 20, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($188.97M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($81.64M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($38.56M) | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | ($116.08M) | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | ($23.40M) | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | ($11.92M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($10.99M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($5.33M) | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | ($2.40M) | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | ($2.12M) | Nov 20, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $537.4K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $2.71M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $4.17M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $8.37M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $15.72M | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | $4.69M | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $2.50M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $617.0K | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | $62.8K | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | $804.2K | Nov 20, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($7.87M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($10.97M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($11.77M) | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | ($15.73M) | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | ($20.61M) | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | ($10.46M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($8.51M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($4.34M) | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | ($1.18M) | Oct 1, 2018 |
| FY2016 | Jun 30, 2016 | ($1.47M) | Sep 28, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2024 | $70.4K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $29.8K | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $5.2K | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $48.9K | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | $184.5K | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $716.7K | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $30.0K | Sep 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.23M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $163.13M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $58.30M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $84.63M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $189.61M | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | $178.10M | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $179.88M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $182.50M | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | $4.52M | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | $870.8K | Nov 20, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $29.58M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $31.15M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $11.80M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $12.01M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $14.94M | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $11.83M | Sep 23, 2020 |
| FY2020 | Jun 30, 2019 | $6.78M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $23.76M | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | $2.99M | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | $1.51M | Nov 20, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($21.35M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $131.98M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $46.50M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $72.62M | Feb 19, 2025 |
| FY2023 | Jun 30, 2021 | $174.66M | Oct 2, 2023 |
| FY2022 | Jun 30, 2020 | $166.27M | Feb 27, 2023 |
| FY2021 | Jun 30, 2019 | $173.10M | Sep 24, 2021 |
| FY2020 | Jun 30, 2018 | $158.74M | Sep 23, 2020 |
| FY2019 | Jun 30, 2017 | $1.53M | Sep 30, 2019 |
| FY2017 | Jun 30, 2016 | ($637.4K) | Nov 20, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.96M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $159.33M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $11.64M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $11.64M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $11.64M | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | $11.64M | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $11.64M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $11.64M | Sep 30, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($510.46M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($332.46M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($244.03M) | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | ($204.35M) | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | ($90.91M) | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | ($64.19M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($52.77M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($34.76M) | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | ($28.44M) | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | ($26.30M) | Nov 20, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $92.7K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $220.5K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $1.87M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | $9.17M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | $20.66M | Feb 27, 2023 |
| FY2022 | Jun 30, 2020 | $8.70M | Feb 27, 2023 |
| FY2021 | Jun 30, 2019 | $12.28M | Sep 24, 2021 |
| FY2020 | Jun 30, 2018 | $15.60M | Sep 23, 2020 |
| FY2019 | Jun 30, 2017 | $3.94M | Sep 30, 2019 |
| FY2017 | Jul 2, 2016 | $23.4K | Nov 20, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Jun 30, 2016 | $102.9K | Sep 28, 2016 |
| FY2014 | Dec 31, 2014 | $100.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $728.0K | Mar 31, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | (2) | Oct 2, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | (2) | Oct 2, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 177.39M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 158.45M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 63.70M | Feb 19, 2025 |
| FY2023 | Jun 30, 2022 | 53.01M | Oct 2, 2023 |
| FY2022 | Jun 30, 2021 | 52.22M | Feb 27, 2023 |
| FY2021 | Jun 30, 2020 | 46.50M | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | 45.27M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | 36.16M | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | 12.43M | Oct 1, 2018 |
| FY2017 | Jun 30, 2016 | 9.53M | Nov 20, 2017 |